Figure 5.

Dnm2 downregulation ameliorates the TA muscle force of Bin1^mck−/− mice

(A) DNM2 protein expression in TA at 8 weeks of age (n = 4; Student’s t test with Welch’s correction). (B) Dnm2 mRNA levels in TA at 8 weeks of age by qRT-PCR for pan-isoforms (n = 4; two-way ANOVA with Bonferroni’s post hoc test). (C) DNM2 protein expression in TA at 8 weeks (n = 4–7; two-way ANOVA with Bonferroni’s post hoc test). (D) Maximal specific force produced by Bin1^fl/fl and Bin1^mck−/− TA. Only muscle force produced by PBS-treated Bin1^mck−/− muscles shows a significant decrease compared to Bin1^fl/fl controls (n = 4–6; Kruskal-Wallis with Dunn’s post hoc test). (E) Specific force produced when stimulated at increasing frequencies (n = 4–6; one-way ANOVA with Tukey’s post hoc test for 1, 25, and 50 Hz frequencies and Kruskal-Wallis with Dunn’s post hoc test for 100 and 125 Hz frequencies). ∗Between Bin1^fl/fl PBS and Bin1^mck−/− PBS. ^βBetween Bin1^mck−/− PBS and Bin1^mck−/− ASO. Graphs in A-C show mean ± SEM, and graphs in D-E shows median ± interquartile range. ∗∗p < 0.01; ∗p < 0.05; ββp < 0.01. We found no statistical difference between Bin1^mck−/− ASO and Bin^fl/fl ASO.